To address this gap, we identified semaphorin 3C (SEMA3C) as a candidate FOXA1 target gene that might mediate the pro-oncogenic effects such as increased proliferation and EMT linked with FOXA1 variants in prostate cancer. The gene discussed is FOXA1; the disease is prostate cancer.